Summary: Cigna Healthcare modified its pharmacogenetic testing coverage policy (Policy 0500), effective May 16, 2026. Here's what billing teams need to know before that date.
Cigna Healthcare updated Policy MM_0500, which governs pharmacogenetic testing coverage across its commercial plans. The policy does not publish a specific policy code in the traditional sense — it's catalogued under the 0500 series in Cigna's coverage position criteria framework. No specific CPT or HCPCS codes are listed in the currently available policy data, which is itself a problem worth addressing. Pharmacogenetic testing billing is already one of the more denial-prone areas in laboratory and genetic testing, and any modification to this coverage policy deserves a close look before the May 16, 2026 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Pharmacogenetic Testing — Coverage Position Criteria (MM_0500) |
| Policy Code | 0500 |
| Change Type | Modified |
| Effective Date | May 16, 2026 |
| Impact Level | High |
| Specialties Affected | Psychiatry, oncology, pain management, cardiology, clinical laboratory, primary care |
| Key Action | Pull and review the full MM_0500 policy document before May 16, 2026, and audit any pharmacogenetic testing claims currently in your queue |
Cigna Pharmacogenetic Testing Coverage Criteria and Medical Necessity Requirements 2026
Pharmacogenetic testing — sometimes called PGx testing — analyzes how a patient's genes affect their response to drugs. It's used across psychiatry, oncology, cardiology, and pain management to guide prescribing decisions. Cigna has historically treated most pharmacogenetic testing as experimental or investigational, except in narrow, well-defined clinical scenarios.
The core question your billing team faces is this: does the specific test, for the specific drug class, for the specific clinical situation meet Cigna's medical necessity criteria under MM_0500? That's not a question you can answer generally. It depends on which gene-drug pair is being tested and what clinical justification supports the order.
The Cigna pharmacogenetic testing coverage policy has been one of the stricter commercial payer positions in this space. Cigna has historically covered PGx testing only when strong evidence links a specific genetic variant to a clinically actionable drug decision — not simply when a physician wants to optimize treatment. "Clinically actionable" is doing a lot of work in that sentence. Cigna's standard is whether the test result will change prescribing in a way that produces a meaningful clinical outcome, not whether it might be useful.
Prior authorization requirements apply to pharmacogenetic testing under Cigna plans. If your team isn't checking prior auth status before these tests are ordered, that's the first place claim denial happens. Prior auth for PGx testing at Cigna is not a formality — denials on this category are frequent and often upheld on appeal when the clinical documentation doesn't specifically address the gene-drug pair being tested and why it changes patient management.
Because the specific criteria changes in this May 2026 modification aren't detailed in the currently available policy data, your billing team should pull the full MM_0500 document directly from Cigna's coverage policy library. The source URL is: https://app.payerpolicy.org/p/cigna/mm_0500_coveragepositioncriteria_pharmacogenetic_testing. Don't work from memory on this one. Pull the document, read it, and compare it to the prior version line by line.
Cigna Pharmacogenetic Testing Exclusions and Non-Covered Indications
This is where Cigna's position has historically been the most consequential for reimbursement. Cigna has generally classified pharmacogenetic testing as experimental or investigational in several broad categories.
Multi-gene panel testing — where a lab runs dozens of gene-drug pairs at once, often called "combinatorial pharmacogenomic testing" — has been a consistent non-covered designation at Cigna. The commercial rationale is that testing genes beyond those with established clinical evidence doesn't meet the medical necessity bar, even if the panel also includes genes that would be covered individually. This is a critical billing distinction. If your lab or ordering provider submits a broad panel when only one or two specific tests have clinical justification, Cigna will deny the whole claim or the non-qualifying components.
Pharmacogenetic testing performed for general wellness, preemptive population screening without a specific clinical trigger, or to satisfy patient curiosity is not covered. The clinical necessity has to be tied to a current prescribing decision, not a hypothetical future one.
Testing in indications where the evidence base hasn't been established to Cigna's standard — which tends to be more conservative than CMS or some other commercial payers — also falls into the non-covered bucket. This is especially relevant in psychiatry, where combinatorial testing for antidepressant selection has been aggressively marketed but where Cigna's coverage has been limited.
Coverage Indications at a Glance
The policy data available for this modification does not include a detailed, indication-level breakdown with specific covered and non-covered criteria. The table below reflects Cigna's general historical coverage framework for pharmacogenetic testing, which this modification updates. Pull the full MM_0500 document to confirm how this framework shifts with the May 2026 change.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Specific single-gene testing tied to a current prescribing decision with established clinical evidence | Generally Covered (when criteria met) | Not listed in available data | Medical necessity documentation required; prior auth applies |
| Multi-gene pharmacogenomic panel testing (combinatorial PGx) | Generally Not Covered / Experimental | Not listed in available data | Cigna has historically denied broad panels as not meeting medical necessity standards |
| Pharmacogenetic testing for oncology drug selection (select scenarios) | Coverage varies by clinical context | Not listed in available data | Evidence threshold varies by gene-drug pair; verify with MM_0500 |
| Pharmacogenetic testing for psychiatric medication selection | Historically limited coverage | Not listed in available data | Combinatorial psychiatric PGx testing has been non-covered at Cigna |
| Preemptive or population-based pharmacogenetic screening | Not Covered | Not listed in available data | No current prescribing decision = no medical necessity under Cigna criteria |
| Pharmacogenetic testing for pain management opioid prescribing | Coverage varies | Not listed in available data | Confirm against current MM_0500 criteria for specific gene-drug pairs |
Cigna Pharmacogenetic Testing Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull the full MM_0500 document before May 16, 2026. The available policy data for this modification doesn't include the specific criteria changes. You need to read the source document to know what shifted. Don't bill to the old criteria after the effective date. |
| 2 | Audit your current pharmacogenetic testing claims in queue. Any claim pending or in process for dates of service on or after May 16, 2026 should be reviewed against the updated MM_0500 criteria. If you're billing for PGx tests ordered in April that won't be submitted until late May, the new policy applies. |
| 3 | Confirm prior authorization status on every Cigna PGx claim. Prior auth requirements for pharmacogenetic testing are strict at Cigna. Document the prior auth number in your claim. If the ordering provider didn't get prior auth before the test was run, your reimbursement exposure is significant. |
| 4 | Review your clinical documentation standards for medical necessity. Cigna's medical necessity criteria for pharmacogenetic testing require documentation that links the specific gene-drug pair to a current, active prescribing decision. Generic language like "to optimize medication management" won't hold up. Work with your ordering providers to document the specific drug being considered and why the genetic result will change the prescribing decision. |
| 5 | Flag any multi-gene panel codes in your charge capture. If your lab or ordering facility runs combinatorial PGx panels, identify which CPT codes are being billed and verify whether those panels meet Cigna's medical necessity threshold under MM_0500. Broad panel billing to Cigna is a high claim denial risk. |
| 6 | Update your prior auth workflows for the May 16, 2026 effective date. If the MM_0500 modification changes which indications require prior auth or adjusts the criteria for approval, your prior auth team needs to know before the effective date. Don't let that update sit with the billing team alone. |
| 7 | Talk to your compliance officer if your volume of Cigna PGx claims is significant. If pharmacogenetic testing billing makes up a meaningful part of your Cigna revenue, this modification warrants a formal compliance review. The policy change is real, the denial risk is high, and the modification details aren't fully published in the available data. That combination is a reason to get your compliance officer and billing consultant in the room before May 16. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Pharmacogenetic Testing Under Policy MM_0500
The available policy data for this Cigna modification does not list specific CPT, HCPCS, or ICD-10 codes. This is a meaningful gap. In practice, pharmacogenetic testing billing involves a range of molecular pathology CPT codes — the 81200 series for specific gene analyses and codes like 81225 and 81226 for CYP2C19 and CYP2D6 variants — but this post will not list codes that aren't confirmed in the policy source document.
What you should do instead:
Pull the full MM_0500 document from Cigna's coverage position library. Cigna typically lists covered and non-covered codes explicitly in their coverage position criteria documents. That code-level detail is what your billing team needs to update charge capture correctly.
If you have access to PayerPolicy's policy comparison tools, run a version diff on MM_0500 to see exactly which codes were added, removed, or reclassified in this modification. That's faster than reading both policy versions side by side.
Until you have confirmed codes from the source document, do not assume that codes previously covered under MM_0500 remain covered after May 16, 2026. That assumption is how denials happen.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.